GenSight Biologics Begins Early Access Treatments for LHON Gene Therapy in France

Event summary

  • First patients treated under French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® on March 19, 2026 at The 15-20 National Hospital in Paris.
  • REVISE dose-ranging study enrolling patients in parallel, with three additional patients treated since February 2026.
  • GS010 targets Leber Hereditary Optic Neuropathy (LHON) caused by ND4 mitochondrial gene mutation, the most common and severe form of LHON.
  • ANSM authorized early access due to urgent need for treatment before irreversible vision loss.

The big picture

This early access program represents a strategic pivot for GenSight Biologics, allowing it to gather real-world data while potentially securing market position in LHON treatment. The parallel REVISE study and AAC program create two pathways for patient access, which could strengthen the therapy's clinical and commercial profile. The focus on the most severe form of LHON highlights GenSight's targeted approach in a niche but critical segment of retinal neurodegenerative diseases.

What we're watching

Regulatory Pathway
Whether the AAC program will accelerate GS010's potential marketing authorization in France and other jurisdictions.
Clinical Execution
The pace at which the REVISE study and AAC program can enroll and treat patients, demonstrating real-world efficacy.
Commercial Strategy
How GenSight Biologics will position GS010 in the market if approved, given its focus on a specific LHON mutation.